Feb 23 (Reuters) - Sanofi SA SASY.PA :
* To return allerject (epinephrine injection, usp) rights to kaléo
* License and development agreement between Sanofi and kaléo will terminate
later this year
* Says Sanofi is in discussions with Kaléo on these terms and for an orderly
transition plan
* Kaléo will evaluate timing and options for bringing allerject back to the
Canadian market
* Source text for Eikon ID:nCNWHCzxpa
* Further company coverage SASY.PA